Skip to main content
SpringerLink
Log in

Resistance to crizotinib and therapeutic options

  • Chapter
  • First Online:
Guide to Targeted Therapies: Treatment Resistance in Lung Cancer

  • 676 Accesses

Abstract

Despite an initial dramatic response, after a median time of 10 months virtually all patients with non-small-cell lung cancer (NSCLC) become refractory to crizotinib due to the emergence of acquired resistance. In addition, approximately 30% of patients do not respond to the therapy even in the presence of the target, anaplastic lymphoma kinase (ALK).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013; 31:1105-1111.

    Google Scholar 

  2. Camidge DR, Doebele RC. Treating ALK-positive lung cancer –early success and future challanges. Nat Rev Clin Oncol. 2012; 9: 268-277.

    Google Scholar 

  3. Camidge DR, Pao W, Sequist L. Acquired resistance to TKIs in solid tumors: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11: 473-481.

    Google Scholar 

  4. Katayama R, Shaw AT, Khna TM, et al. Mechanisms of acquired crizotinib resistance in ALK rearranged lung cancers. Science Transl Med. 2012; 4;120ra17.

    Google Scholar 

  5. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363: 1734-1739.

    Google Scholar 

  6. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010; 70; 10038-10043.

    Google Scholar 

  7. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472-1482.

    Google Scholar 

  8. Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013; 3: 430-443.

    Google Scholar 

  9. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3 K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010; 70: 9827-9836.

    Google Scholar 

  10. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13: 1011-1019.

    Google Scholar 

  11. Pop O, Pirvu A, Toffart AC, et al. Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thor Oncol. 2012; 8: e1-e8.

    Google Scholar 

  12. Kuriyama Y, Kim YH, Nagai H, et al. Disease flare after discontinuation of crizotinib in Anaplastic Lymphoma Kinase positive lung cancer. Case Rep Oncol. 2013; 6: 430-433.

    Google Scholar 

  13. Weickhardt AJ, ScheierB, BurkeJM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1807-1814.

    Google Scholar 

  14. Ou S-H I, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014; 25: 415-422.

    Google Scholar 

  15. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370: 1189-1197.

    Google Scholar 

  16. Ou S, Gadgeel S, Chiappori A, et al. Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028). Eur J Cancer. 2013; 49(suppl3): s19.

    Google Scholar 

  17. Seto T, Katsuyuki K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1/2 study. Lancet Oncol. 2013; 14:590-598.

    Google Scholar 

  18. Camidge DR, Bazhenova L, Salgia R, et al. Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. J Thorac Oncol. 2013; 8: S296.

    Google Scholar 

  19. Horn L, Infante JR, Blumenschein GR, et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014; 32 (5 s): abstr 8030.

    Google Scholar 

  20. Zou HY, Li Q, Engstrom LD. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015;112:3493-3498.

    Google Scholar 

  21. Mori M, Ueno Y, Konagai S, et al. Selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol CancerTher.2014;13:329-340.

    Google Scholar 

  22. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008; 68:2850-2860.

    Google Scholar 

  23. Stühmer T, Zöllinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 2008; 22:1604-1612.

    Google Scholar 

  24. Ueno T, Tsukuda K, Toyooka S, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 2012; 76: 26-31.

    Google Scholar 

  25. Felip E, Carcereny E, Barlesi F, et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-Rearranged (ALK +) or EGFR mutated advanced non-small cell lung cancer. Ann Oncol. 2012; 23: ix152–ix174.

    Google Scholar 

  26. Samuel TA, Sessa C, Britten C, et al. AUY922, a novel HSP90 inhibitor: final results of a first-inhuman study in patients with advanced solid malignancies. J Clin Oncol. 2010; 28 (abstr 2528).

    Google Scholar 

  27. Wang Y, Trepel JB, Neckers LM, et al. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs. 2010 Dec; 11:1466-1476.

    Google Scholar 

  28. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19:3068-3077.

    Google Scholar 

  29. Ramalingam SS, Goss GD, Andric ZG, et al. The GALAXY trial: a randomized IIB/III Study of Ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone as second line therapy in patients with stage IIIB or IV NSCLC. Ann Oncol. 2012; 23 (abstract 1248P).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Toscano Tumori, Ospedale Civile di Livorno, viale Alfieri 36, 57100, Livorno, Italy

    Federico Cappuzzo

Authors
  1. Federico Cappuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Cappuzzo, F. (2015). Resistance to crizotinib and therapeutic options. In: Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Adis, Cham. https://doi.org/10.1007/978-3-319-20741-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20741-4_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-20740-7

  • Online ISBN: 978-3-319-20741-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation